Cartesian Therapeutics, revealed that the initial patient has been treated in its Phase 2 open-label clinical study assessing Descartes-08 in individuals with systemic lupus erythematosus.

Checkpoint Therapeutics has announced the successful resubmission of its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for cosibelimab.

BioCity reveals SC0062, an endothelin receptor A selective antagonist, has achieved its main objective in a Phase 2 study (2-SUCCEED) for IgA nephropathy. The trial was randomized, double-blind, and placebo-controlled.

Epsilogen reveals CTA green light for Phase Ib study of MOv18 IgE in platinum-refractory ovarian cancer.

CSL Behring Treats First Hemophilia B Patients in Europe with HEMGENIX® (etranacogene dezaparvovec) Gene Therapy.

Johnson & Johnson revealed that the U.S. Food and Drug Administration has granted conventional approval for SIRTURO (bedaquiline).

Sobi submits biologics license application to the FDA for SEL-212, targeting chronic refractory gout treatment.

Tyra Biosciences has reported preclinical proof-of-concept findings for TYRA-300, an experimental orally administered FGFR3 selective inhibitor.

Satellos Reveals Initial Data Indicating Muscle Recovery and Healing from SAT-3247 Treatment in Dog Model of Duchenne Muscular Dystrophy (DMD).

The U.S. FDA has granted approval for Kisunla™ (donanemab-azbt, 350 mg/20 mL once-monthly injection for IV infusion), developed by Eli Lilly and Company.

Eirion Therapeutics Inc. has reported the enrollment of the initial participant in a Phase 1 clinical study aimed at assessing the safety of their proprietary topical medication, ET-02, for the treatment of androgenic alopecia.

KaliVir Immunotherapeutics Receives FDA Approval for Investigational New Drug VET3-TGI in Solid Tumor Immunotherapy.